Core Viewpoint - Goldman Sachs has introduced the concept of "Chinese Prominent 10," which includes ten major private enterprises in China, aiming to identify core assets with long-term dominance potential in the Chinese stock market, similar to the "Magnificent 7" in the US [2][3]. Group 1: Overview of the "Chinese Prominent 10" - The "Chinese Prominent 10" includes Tencent (market cap $601 billion), Alibaba ($289 billion), Xiaomi ($146 billion), BYD ($121 billion), Meituan ($102 billion), NetEase ($86 billion), Midea ($78 billion), Hengrui Medicine ($51 billion), Trip.com ($43 billion), and Anta ($35 billion) [4]. - These companies span various sectors such as technology, consumer goods, and automotive, representing new economic drivers in China, including AI, self-sufficiency, globalization, and service consumption upgrades [2][5]. Group 2: Financial Performance and Valuation - The expected compound annual growth rate (CAGR) for the earnings of these companies over the next two years is projected to be 13%, with a median of 12% [6]. - The average price-to-earnings (P/E) ratio for these stocks is 16 times, with a forward price-to-earnings growth (fPEG) ratio of 1.1, making them more attractive compared to the US "Magnificent 7," which has a P/E of 28.5 and an fPEG of 1.8 [6]. Group 3: Market Trends and Recovery - Since the low point at the end of 2022, the average increase in these ten stocks has been 54%, with a year-to-date rise of 24%, outperforming the MSCI China Index by 33 and 8 percentage points, respectively [7]. - Private enterprises in China are showing strong recovery signs after a significant market value loss of nearly $4 trillion since the end of 2020 [8]. Group 4: Policy and Technological Drivers - The Chinese government has increased its focus on private enterprises, with significant policy events boosting confidence among private business owners [10]. - Rapid advancements in AI technology, particularly with the emergence of models like DeepSeek-R1, have enhanced market optimism towards technology-driven private enterprises [11]. Group 5: Market Concentration and Growth Potential - The concentration of the Chinese stock market is relatively low, with the top ten companies accounting for only 17% of the total market value, compared to 33% in the US [13]. - As leading companies expand their dominance, market concentration is expected to increase in the coming years [14]. Group 6: Global Expansion and Profitability - Private enterprises are leading the "going out" strategy, with overseas sales increasing from 10% in 2017 to an estimated 17% in 2024 [19]. - Companies with strong balance sheets and cash flows are better positioned to benefit from overseas expansion, with some, like BYD, achieving significantly higher gross margins abroad [19]. Group 7: Valuation and Investment Opportunities - Despite improving fundamentals, the valuation of the "Chinese Prominent 10" remains at historical lows, with an average trading valuation of 13.9 times the expected P/E ratio, only 22% higher than the MSCI China Index [20]. - If these private enterprises achieve similar valuation premiums as their US counterparts, their market concentration could increase, adding $313 billion in market value [21].

Group 1 - Goldman Sachs' chief China equity strategist Liu Jinjun's team has released a series of reports indicating that the mid-term investment value of Chinese private enterprises has improved due to macroeconomic, policy, and micro factors [1] - The research team has identified the "Top Ten Private Enterprises" in China, which includes Tencent, Alibaba, Xiaomi, BYD, Meituan, NetEase, Midea, Hansoh Pharmaceutical, Ctrip, and Anta, similar to the "Big Seven" in the US stock market [1] - Goldman Sachs expects these "Top Ten Private Enterprises" to expand their dominance in the Chinese stock market, with all stocks rated as "Buy" by analysts [1] Group 2 - The total market capitalization of the "Top Ten Private Enterprises" is estimated at $1.6 trillion, accounting for 42% of the MSCI China Index weight, with an average daily trading volume of $11 billion [1] - The projected compound annual growth rate (CAGR) for earnings per share (EPS) over the next two years is 13%, indicating high market influence and investment appeal [1] - These enterprises demonstrate significant advantages in market capitalization, trading volume, profit growth potential, and valuation, making them worthy of investor attention [1] Group 3 - In the equity market, there are 5,121 listed private enterprises, with 3,771 listed on the A-share market and 1,350 on offshore markets, totaling a market capitalization of $9 trillion, which is 71% of the total MSCI China Index market capitalization [2] - The earnings weight of these private enterprises accounts for 31% of the index [2]

Core Viewpoint - The mid-term investment outlook for Chinese private enterprises is improving due to various macro, policy, and micro factors, as highlighted in a recent report by Goldman Sachs' chief China equity strategist Liu Jinjun [1] Group 1: Investment Opportunities - Goldman Sachs has identified a list of ten favored Chinese private listed companies, referred to as the "Ten Giants," which include Tencent, Alibaba, Xiaomi, BYD, Meituan, NetEase, Midea, Hengrui Medicine, Ctrip, and Anta [1] - The total market capitalization of these ten companies is approximately $1.6 trillion, accounting for 42% of the MSCI China Index weight, with a daily trading volume of $11 billion [1] - Analysts at Goldman Sachs project a 13% growth in earnings (compound annual growth rate) for the "Ten Giants" over the next two years, with a price-to-earnings ratio of 16 times [1] Group 2: Economic Themes - The "Ten Giants" are expected to reflect the latest economic themes in China, including advancements in artificial intelligence/technology, international expansion, new consumption trends, and enhanced shareholder returns [1] - Goldman Sachs emphasizes that investing in private enterprises does not exclude the preference for high-quality state-owned enterprises and shareholder return combinations [1]

Core Viewpoint - The recent trend of leading A-share companies listing on H-shares is gaining momentum, with several companies successfully completing their listings in Hong Kong, enhancing their international market presence and brand recognition [1][2]. Group 1: H-share Listing Trend - Leading companies like Midea Group, CATL, and Heng Rui Pharmaceutical have recently listed on the Hong Kong Stock Exchange, indicating a growing trend among A-share companies to seek H-share listings [1]. - Stone Technology announced its intention to list on the Hong Kong Stock Exchange, further contributing to the ongoing "H-share boom" [2]. Group 2: Investment Considerations - Investors face a dilemma regarding whether to invest in A-shares or H-shares of companies listed on both exchanges, as each market has distinct advantages and disadvantages [2]. - Analysts highlight that H-shares generally trade at a discount compared to A-shares due to differences in investor structure, liquidity, and refinancing mechanisms [3][5]. Group 3: Price Discrepancies - The long-term price discrepancy between A-shares and H-shares is attributed to the lack of free convertibility and arbitrage mechanisms between the two markets [3]. - Currently, only 155 companies are listed on both A and H-shares, representing a small fraction of the total number of companies on the Hong Kong main board [5][6]. Group 4: Sector Analysis - The majority of companies listed on both exchanges are state-owned enterprises and belong to traditional economic sectors, such as finance and energy, which tend to attract dividend-focused investors [6]. - The analysis suggests that the price differences between A and H-shares can be better understood through a dividend perspective rather than purely market sentiment [6]. Group 5: Recent Market Dynamics - The phenomenon of "A-H share price inversion" has been observed, particularly with companies like CATL, where H-shares traded at a premium to A-shares, indicating a shift in market dynamics [7][9]. - The current macroeconomic environment and differing investor preferences contribute to the observed price behaviors between A and H-shares [9][10]. Group 6: Future Outlook - Companies like Stone Technology, which have a significant portion of their revenue from overseas markets, are expected to attract foreign investment and may experience similar price dynamics as seen with CATL [12][13]. - The ongoing trend of high dividend yields in the Hong Kong market, coupled with structural opportunities in sectors like new consumption and technology, positions H-shares favorably for investors [16][17].

Group 1 - The core point of the news is that Heng Rui Pharmaceutical's stock price is recovering, while a senior executive plans to reduce holdings for personal financial needs [1] - Senior Vice President Sun Jieping intends to sell up to 476,700 shares, representing 0.007% of the company's total shares, potentially cashing out approximately 25.69 million yuan based on the latest closing price of 53.89 yuan per share [1] - The company's stock price has seen a significant increase from 45.7 yuan per share to 53.89 yuan per share, marking a 17.9% rise in 2025 [1] Group 2 - In 2024, Heng Rui Pharmaceutical achieved record-high revenue of 27.985 billion yuan, a year-on-year increase of 22.63%, and a net profit of 6.337 billion yuan, up 47.28% [2] - The growth in performance is attributed to the increase in innovative drug sales, which reached 13.892 billion yuan, reflecting a 30.60% year-on-year growth [2] - In the first quarter of 2025, the company continued its growth trend with revenue of 7.206 billion yuan, a 20.14% increase, and a net profit of 1.874 billion yuan, up 36.9% [2] Group 3 - Heng Rui Pharmaceutical successfully listed on the Hong Kong Stock Exchange on May 23, raising a net amount of 9.747 billion HKD, attracting several prominent cornerstone investors [3] - As of June 16, the stock price in Hong Kong was 59.5 HKD per share, representing a 35% increase from the issue price of 44.05 HKD per share [4]

Financial Sector - The banking sector continued its upward trend in the afternoon session, contributing positively to the FTSE China A50 Index [1] - China Life Insurance, China Pacific Insurance, and China Ping An reported market capitalizations of 385.19 billion, 351.05 billion, and 989.18 billion respectively, with trading volumes of 1.155 billion, 2.698 billion, and 1.079 billion [4] Alcohol Industry - Kweichow Moutai, Shanxi Fenjiu, and Wuliangye had market capitalizations of 1,786.68 billion, 210.10 billion, and 459.08 billion respectively, with trading volumes of 3.192 billion, 6.060 billion, and 1.760 billion [4] - Kweichow Moutai's stock price decreased by 4.66 (-0.33%), while Wuliangye increased by 1.12 (+0.65%) [4] Semiconductor Industry - Northern Huachuang, Haiguang Information, and Cambricon Technologies had market capitalizations of 220.29 billion, 249.45 billion, and 321.57 billion respectively, with trading volumes of 1.075 billion, 2.756 billion, and 2.048 billion [4] - Northern Huachuang's stock price fell by 7.35 (-1.22%) [4] Automotive Industry - BYD, Great Wall Motors, and Shanghai-Kunming High-Speed Railway had market capitalizations of 1,892.53 billion, 183.68 billion, and 281.32 billion respectively, with trading volumes of 3.509 billion, 0.627 billion, and 0.348 billion [4] - BYD's stock price decreased by 1.57 (-0.45%) [4] Energy Sector - COSCO Shipping Holdings, Sinopec, and China National Petroleum Corporation had market capitalizations of 716.56 billion, 1,650.85 billion, and 249.69 billion respectively, with trading volumes of 1.159 billion, 1.722 billion, and 1.019 billion [4] - Sinopec's stock price increased by 0.03 (+0.33%) [4] Coal Industry - Shaanxi Coal and Chemical Industry, China Shenhua Energy, and CATL had market capitalizations of 191.77 billion, 1,124.60 billion, and 775.67 billion respectively, with trading volumes of 3.014 billion, 0.922 billion, and 0.608 billion [4] - Shaanxi Coal's stock price decreased by 0.22 (-0.56%) [4] Food and Beverage Sector - China National Nuclear Power, Dongfang Fortune, and Haitian Flavoring had market capitalizations of 745.30 billion, 193.55 billion, and 343.42 billion respectively, with trading volumes of 1.574 billion, 0.521 billion, and 5.827 billion [5] - China National Nuclear Power's stock price decreased by 0.16 (-0.52%) [5] Consumer Electronics - Heng Rui Medicine, Industrial Fulian, and Luxshare Precision had market capitalizations of 355.01 billion, 421.40 billion, and 231.31 billion respectively, with trading volumes of 2.645 billion, 3.052 billion, and 2.100 billion [5] - Heng Rui's stock price increased by 0.32 (+1.53%) [5] Logistics Industry - Mindray Medical, SF Holding, and Wanhua Chemical had market capitalizations of 169.95 billion, 248.64 billion, and 286.88 billion respectively, with trading volumes of 1.343 billion, 0.896 billion, and 1.030 billion [5] - Mindray's stock price increased by 0.81 (+1.65%) [5] Telecommunications - Zijin Mining, China State Construction, and China Unicom had market capitalizations of 500.19 billion, 236.77 billion, and 164.76 billion respectively, with trading volumes of 2.515 billion, 0.784 billion, and 0.731 billion [5] - Zijin Mining's stock price decreased by 0.33 (-1.72%) [5]

Group 1 - The core viewpoint of the report is that the mid-term investment outlook for Chinese private enterprises is improving due to various macro, policy, and micro factors [1] - Goldman Sachs has identified a list of "Ten Giants" among Chinese private companies, which includes Tencent, Alibaba, Xiaomi, BYD, Meituan, NetEase, Midea, Hengrui Medicine, Ctrip, and Anta, covering multiple sub-industries [1] - These "Ten Giants" represent five major investment trends: AI/technology development, self-sufficiency, globalization, service consumption, and improved shareholder returns in China [1] Group 2 - The "Ten Giants" are expected to have a compound annual growth rate (CAGR) of 13% over the next two years, with an average price-to-earnings (P/E) ratio of 16 times, making them more attractive compared to the U.S. "Seven Sisters" [2] - The average trading valuation of the "Ten Giants" is 13.9 times the expected 12-month P/E ratio, which is only a 22% premium over the MSCI China Index, significantly lower than the historical average and the 43% premium of the U.S. tech giants [2] - If Chinese private enterprises achieve a valuation premium similar to that of the U.S., their market concentration could increase from 11% to 13%, adding $313 billion in market value [2] Group 3 - AI technology is expected to drive a 2.5% annual profit growth for Chinese companies over the next decade, with private enterprises accounting for 72% of the defined AI-tech universe [3] - Private enterprises in the technology sector show significantly higher attention to AI compared to their peers, as analyzed from over 1,300 earnings call reports [3] - Companies that have a large customer base and data, and are embracing new AI technologies, are more likely to become long-term winners [3]

金十图示：2025年06月16日（周一）富时中国A50指数成分股午盘收盘行情一览：银行股普涨、汽车整车板块领跌 富时中国A50指数连续 保险 账 中国人保 中国太保 中国平安 081 3803.26亿市值 3472.94亿市值 9855.38亿市值 14.94亿成交额 5.15亿成交额 5.27亿成交额 54.12 36.10 8.60 +0.19(+0.53%) -0.36(-0.66%) +0.10(+1.18%) 酸酒行业 贵州茅台 五粮液 山西汾酒 17760.63亿市值 2099.19亿市值 4565.94亿市值 39.48亿成交额 10.73亿成交额 21.62亿成交额 117.63 1413.84 172.07 -13.11(-0.92%) -1.49(-1.25%) +0.97(+0.57%) 半导体 北方华创 寒武纪-U 海光信息 HYGON 2207.27亿市值 2517.14亿市值 3204.56亿市值 14.65亿成交额 7.50亿成交额 16.77亿成交额 413.21 602.97 137.87 -1.93(-0.32%) +2.65(+0.65%) +0.81(+0.59%) 汽 ...

Group 1 - Goldman Sachs has introduced the concept of "Chinese Prominent 10," which includes major private companies like Tencent, Alibaba, and Xiaomi, aiming to identify core assets in the Chinese stock market with long-term dominance potential [1][2] - The total market capitalization of these ten companies is approximately $1.6 trillion, representing 42% of the MSCI China Index, with an expected compound annual growth rate (CAGR) of 13% in earnings over the next two years [1][2] - The "Chinese Prominent 10" spans various high-growth sectors, including technology, consumer goods, and automotive, reflecting new economic drivers such as AI, self-sufficiency, globalization, and service consumption upgrades [1][2] Group 2 - The selected "Chinese Prominent 10" companies include Tencent ($601 billion), Alibaba ($289 billion), Xiaomi ($146 billion), BYD ($121 billion), Meituan ($102 billion), NetEase ($86 billion), Midea ($78 billion), Hengrui Medicine ($51 billion), Trip.com ($43 billion), and Anta ($35 billion) [2] - These companies collectively account for a daily trading volume of $11 billion, indicating significant market influence and investment appeal [2] - The average price-to-earnings (P/E) ratio for these companies is 16 times, with a forward price-to-earnings growth (fPEG) ratio of 1.1, making them more attractive compared to the U.S. "Magnificent 7" with a P/E of 28.5 and fPEG of 1.8 [2] Group 3 - Since the low point at the end of 2022, the average increase in stock prices for these ten companies has been 54%, with a year-to-date rise of 24%, outperforming the MSCI China Index by 33 and 8 percentage points, respectively [3] Group 4 - Following a significant market value loss of nearly $4 trillion since late 2020, private enterprises in China are showing signs of strong recovery, with profits and return on equity (ROE) rebounding by 22% and 1.2 percentage points, respectively, since 2022 [4] - Recent policies have increased the focus on private enterprises, boosting confidence among entrepreneurs, as evidenced by the private enterprise symposium in February and the introduction of the first Private Economy Promotion Law in April [4] - The rapid advancements in AI technology, particularly with the emergence of models like DeepSeek-R1, have enhanced market optimism towards technology-driven private enterprises [4] Group 5 - The concentration of the Chinese stock market is relatively low, with the top ten companies accounting for only 17% of the total market capitalization, compared to 33% in the U.S. and 30% in other emerging markets [6] - As leading companies expand their dominance, market concentration is expected to increase in the coming years [6] Group 6 - The investment interest from private enterprises is anticipated to support organic growth and acquisitions, aided by a more transparent and relaxed merger and acquisition framework [7] Group 7 - The average turnover rate of the top ten companies in China over the past decade has been only 12%, indicating strong competitive advantages and market "stickiness" among leading firms [8] - Factors such as capital expenditure, R&D investment, and market concentration are positively correlated with subsequent stock returns and market share representation [8] Group 8 - AI technology is reshaping the competitive landscape, with large private enterprises leveraging their customer base, data accumulation, and investment capabilities to excel in AI development and commercialization [9][10] - Private enterprises are leading the "going global" strategy, with overseas sales increasing from 10% in 2017 to an estimated 17% in 2024 [10] - Companies with strong balance sheets and cash flows are better positioned to capitalize on overseas market opportunities, where profit margins can be significantly higher than in domestic markets [10] Group 9 - Despite ongoing improvements in fundamentals, the valuations of the "Chinese Prominent 10" remain at historical lows, with an average trading valuation of 13.9 times the expected P/E ratio, only 22% higher than the MSCI China Index [11] - If these private enterprises achieve similar valuation premiums as their U.S. counterparts, their market concentration could increase from 11% to 13%, adding approximately $313 billion in market value [11]

华福证券认为，港股创新药（含Pharma）为医药板块中最强势的板块，其次为创新药产业链CRO板 块，创新药已成为市场认可的主线之一，个股方面从主流一二线标的，行情亦在向有创新药布局或BD 预期的中药或仿制药标的扩展。短期创新药建议积极拥抱龙头和一线标的。 （本文机构观点来自持牌证券机构，不构成任何投资建议，亦不代表平台观点，请投资人独立判断和决 策。） 消息面上，据央视新闻，6月13日国务院常务会议召开研究优化药品和耗材集采有关举措。会议指出， 要加强药品和耗材集采政策评估，总结经验、补齐短板，推动集采工作规范化制度化常态化开展。要更 好促进"三医"协同发展和治理，完善公立医院补偿机制，支持医药企业提高创新能力，更好满足群众多 元化就医用药需求。要加强对药品和耗材生产、流通、使用全链条质量监管，扎实推进仿制药质量和疗 效一致性评价，让人民群众用药放心安心。 东吴证券指出，创新药BD推动及优秀临床数据下，看好的医药子行业排序分别为：创新药>CXO>中药 >医疗器械>药店>医药商业等。具体标的选择思路：从成长性角度选股，主要集中创新药领域；从左侧 角度选股，主要集中在CXO、医疗器械。 6月16日，创新药概念小幅 ...